Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Oncology Pubmed

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

The Lancet Oncology , Volume 16 (13): -1290 – Jan 13, 2016

Loading next page...
 
/lp/pubmed/comparison-of-dabrafenib-and-trametinib-combination-therapy-with-3Ay2xFqMcB

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1470-2045
DOI
10.1016/S1470-2045(15)00087-X
pmid
26433819

Abstract

Journal

The Lancet OncologyPubmed

Published: Jan 13, 2016

There are no references for this article.